Literature DB >> 19139851

Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.

Xiang Yang Zhang1, Dong Feng Zhou, Ling Yan Qi, Song Chen, Lian Yuan Cao, Da Chun Chen, Mei Hong Xiu, Fan Wang, Gui Ying Wu, Lin Lu, Therese A Kosten, Thomas R Kosten.   

Abstract

OBJECTIVE: Both schizophrenia and oxidative stress have been associated with immune system abnormalities in interleukin-2 and -6 (IL-2; IL-6) and increases in superoxide dismutase (SOD) activity. These abnormalities may improve during antipsychotic drug treatment that reduces symptoms in schizophrenic patients.
MATERIALS AND METHODS: Subjects included 30 healthy controls (HC) and 78 schizophrenic (SCH) in-patients who were randomly assigned to 12 weeks of double-blind treatment with risperidone 6 mg/day or haloperidol 20 mg/day. Ratings using the Positive and Negative Syndrome Scale (PANSS) were correlated with blood SOD and serum IL-2 levels.
RESULTS: SCH patients who were medication-free for 2 weeks had greater SOD, IL-2, and IL-6 levels than HC. At baseline, these SOD elevations were associated with higher PANSS total scores and the IL-2 elevations with lower PANSS positive symptom scores. The SOD and IL-2 levels in the SCH were also positively correlated. After treatment, PANSS positive symptoms and both SOD and IL-2 showed a significant decrease, but IL-6 showed no change. The SOD and IL-2 reductions were correlated with the reductions in PANSS total score, and SOD reductions also correlated with positive subscore reductions. Females showed these associations more strongly than males.
CONCLUSION: Our results suggest that the dysregulation in the cytokine system and oxidative stress in patients with schizophrenia is implicated in clinical symptoms and is improved at least partially with antipsychotic treatment. The stronger associations in females deserve further study and confirmation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139851     DOI: 10.1007/s00213-008-1447-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  55 in total

Review 1.  The role of immune function in schizophrenia: an overview.

Authors:  N Müller; M Riedel; M Ackenheil; M J Schwarz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

Review 2.  Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review).

Authors:  R Schreck; K Albermann; P A Baeuerle
Journal:  Free Radic Res Commun       Date:  1992

3.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

4.  Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment.

Authors:  V Arolt; M Rothermundt; K P Wandinger; H Kirchner
Journal:  Mol Psychiatry       Date:  2000-03       Impact factor: 15.992

Review 5.  Free radical pathology and antioxidant defense in schizophrenia: a review.

Authors:  S P Mahadik; S Mukherjee
Journal:  Schizophr Res       Date:  1996-03       Impact factor: 4.939

6.  Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Pei Yan Zhang; Gui Ying Wu; Lian Yuan Cao; Yu Cun Shen
Journal:  Schizophr Res       Date:  2002-10-01       Impact factor: 4.939

7.  Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers.

Authors:  M Maes; E Bosmans; J Calabrese; R Smith; H Y Meltzer
Journal:  J Psychiatr Res       Date:  1995 Mar-Apr       Impact factor: 4.791

8.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

Authors:  P A Janssen; C J Niemegeers; F Awouters; K H Schellekens; A A Megens; T F Meert
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

9.  Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia.

Authors:  J K Yao; C G Sistilli; D P van Kammen
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2003-12       Impact factor: 4.006

10.  Cytokine production in drug-free and neuroleptic-treated schizophrenic patients.

Authors:  H Bessler; Z Levental; L Karp; I Modai; M Djaldetti; A Weizman
Journal:  Biol Psychiatry       Date:  1995-09-01       Impact factor: 13.382

View more
  15 in total

1.  Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13.

Authors:  Zuzana Tobiasova; Klaas H B van der Lingen; Lawrence Scahill; James F Leckman; Yan Zhang; Wookjin Chae; James T McCracken; Christopher J McDougle; Benedetto Vitiello; Elaine Tierney; Michael G Aman; L Eugene Arnold; Liliya Katsovich; Pieter J Hoekstra; Fred Volkmar; Alfred L M Bothwell; Ivana Kawikova
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-11-09       Impact factor: 2.576

Review 2.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

3.  Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Peter Buckley; Wesley Seabolt; Andrew Mellor; Brian Kirkpatrick
Journal:  Biol Psychiatry       Date:  2011-06-08       Impact factor: 13.382

4.  Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis.

Authors:  Janine A E M van Venrooij; Sjoerd B A H A Fluitman; Jeroen G Lijmer; Annemieke Kavelaars; Cobi J Heijnen; Herman G M Westenberg; René S Kahn; Christine C Gispen-de Wied
Journal:  Schizophr Bull       Date:  2010-06-17       Impact factor: 9.306

Review 5.  Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia.

Authors:  Narasimha M Beeraka; Marco F Avila-Rodriguez; Gjumrakch Aliev
Journal:  Mol Neurobiol       Date:  2022-01-27       Impact factor: 5.590

Review 6.  Evidence for a dysregulated immune system in the etiology of psychiatric disorders.

Authors:  Sinead M Gibney; Hemmo A Drexhage
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-05       Impact factor: 4.147

7.  Salivary Stress-Related Responses in Tinnitus: A Preliminary Study in Young Male Subjects with Tinnitus.

Authors:  Ola A Alsalman; Denise Tucker; Sven Vanneste
Journal:  Front Neurosci       Date:  2016-07-20       Impact factor: 4.677

8.  The reduction of CSF tumor necrosis factor alpha levels in schizophrenia: no correlations with psychopathology and coincident metabolic characteristics.

Authors:  Haibing Zhu; Danfeng Wang; Xiuqin Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2016-11-03       Impact factor: 2.570

Review 9.  Neuroprotection in Schizophrenia and Its Therapeutic Implications.

Authors:  Yong-Ku Kim; Kyoung-Sae Na
Journal:  Psychiatry Investig       Date:  2017-07-11       Impact factor: 2.505

Review 10.  Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials.

Authors:  Stefano Marini; Domenico De Berardis; Federica Vellante; Rita Santacroce; Laura Orsolini; Alessandro Valchera; Gabriella Girinelli; Alessandro Carano; Michele Fornaro; Francesco Gambi; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Mediators Inflamm       Date:  2016-07-25       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.